Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Other Accumulated Expenses (2022 - 2025)

Historic Other Accumulated Expenses for Mereo BioPharma (MREO) over the last 4 years, with Q3 2025 value amounting to $622000.0.

  • Mereo BioPharma's Other Accumulated Expenses fell 7647.5% to $622000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $622000.0, marking a year-over-year decrease of 7647.5%. This contributed to the annual value of $1.1 million for FY2024, which is 724.78% up from last year.
  • As of Q3 2025, Mereo BioPharma's Other Accumulated Expenses stood at $622000.0, which was down 7647.5% from $777000.0 recorded in Q2 2025.
  • Over the past 5 years, Mereo BioPharma's Other Accumulated Expenses peaked at $3.4 million during Q2 2024, and registered a low of $622000.0 during Q3 2025.
  • Over the past 4 years, Mereo BioPharma's median Other Accumulated Expenses value was $1.0 million (recorded in 2023), while the average stood at $1.4 million.
  • Data for Mereo BioPharma's Other Accumulated Expenses shows a peak YoY increase of 2451.25% (in 2025) and a maximum YoY decrease of 7737.99% (in 2025) over the last 5 years.
  • Over the past 4 years, Mereo BioPharma's Other Accumulated Expenses (Quarter) stood at $1.1 million in 2022, then dropped by 4.67% to $1.0 million in 2023, then rose by 7.25% to $1.1 million in 2024, then plummeted by 43.2% to $622000.0 in 2025.
  • Its Other Accumulated Expenses was $622000.0 in Q3 2025, compared to $777000.0 in Q2 2025 and $894000.0 in Q1 2025.